Literature DB >> 33712017

Rapid diagnostic test negative Plasmodium falciparum malaria in a traveller returning from Ethiopia.

Stefan Schlabe1,2, Ingrid Reiter-Owona3, Tamara Nordmann4,5, Ramona Dolscheid-Pommerich6, Egbert Tannich5, Achim Hoerauf3,7, Jürgen Rockstroh4,7.   

Abstract

BACKGROUND: Plasmodium falciparum strains with mutations/deletions of the genes encoding the histidine-rich proteins 2/3 (pfhrp2/3) have emerged during the last 10 years leading to false-negative results in HRP2-based rapid diagnostic tests (RDTs). This can lead to unrecognized infections in individuals and to setbacks in malaria control in endemic countries where RDTs are the backbone of malaria diagnostics and control. CASE DESCRIPTION: Here the detection of a pfhrp2/3-negative P. falciparum infection acquired in Ethiopia by a 63-year old female traveller is presented. After onset of symptoms during travel, she was first tested negative for malaria, most probably by RDT, at a local hospital in Harar, Ethiopia. Falciparum malaria was finally diagnosed microscopically upon her return to Germany, over 4 weeks after infection. At a parasite density of approximately 5387 parasites/µl, two different high-quality RDTs: Palutop + 4 OPTIMA, NADALRMalaria PF/pan Ag 4 Species, did not respond at their respective P. falciparum test lines. pfhrp2/3 deletion was confirmed by multiplex-PCR. The patient recovered after a complete course of atovaquone and proguanil. According to the travel route, malaria was acquired most likely in the Awash region, Central Ethiopia. This is the first case of imported P. falciparum with confirmed pfhrp2/3 deletion from Ethiopia.
CONCLUSION: HRP2-negative P. falciparum strains may not be recognized by the presently available HRP2-based RDTs. When malaria is suspected, confirmation by microscopy and/or qPCR is necessary in order to detect falciparum malaria, which requires immediate treatment. This case of imported P. falciparum, non-reactive to HRP2-based RDT, possibly underlines the necessity for standardized, nationwide investigations in Ethiopia and should alert clinicians from non-endemic countries to the possibility of false-negative RDT results which may increase in returning travellers with potentially life-threatening infections.

Entities:  

Keywords:  Ethiopia; HRP2; Malaria; RDT

Year:  2021        PMID: 33712017      PMCID: PMC7952815          DOI: 10.1186/s12936-021-03678-2

Source DB:  PubMed          Journal:  Malar J        ISSN: 1475-2875            Impact factor:   2.979


  22 in total

1.  Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test.

Authors:  Sandrine Houzé; Véronique Hubert; Gaëlle Le Pessec; Jacques Le Bras; Jérôme Clain
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

2.  Lineage-Specific Expansion of Plasmodium falciparum Parasites With pfhrp2 Deletion in the Greater Mekong Subregion.

Authors:  Justin Gibbons; Junling Qin; Pallavi Malla; Zenglei Wang; Awtum Brashear; Chengqi Wang; Jun Miao; John H Adams; Kami Kim; Rays Jiang; Liwang Cui
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

3.  Pfhrp2-Deleted Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional Survey.

Authors:  Jonathan B Parr; Robert Verity; Stephanie M Doctor; Mark Janko; Kelly Carey-Ewend; Breanna J Turman; Corinna Keeler; Hannah C Slater; Amy N Whitesell; Kashamuka Mwandagalirwa; Azra C Ghani; Joris L Likwela; Antoinette K Tshefu; Michael Emch; Jonathan J Juliano; Steven R Meshnick
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  Diagnostic performance of rapid diagnostic tests for the diagnosis of malaria at public health facilities in north-west Ethiopia.

Authors:  Gebeyaw Getnet; Sisay Getie; Mitaly Srivastava; Wubet Birhan; Abebe A Fola; Harald Noedl
Journal:  Trop Med Int Health       Date:  2015-08-26       Impact factor: 2.622

5.  Plasmodium falciparum histidine rich protein-2 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana.

Authors:  Linda Eva Amoah; Joana Abankwa; Akua Oppong
Journal:  Malar J       Date:  2016-02-18       Impact factor: 2.979

6.  False-negative malaria rapid diagnostic tests in Rwanda: impact of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission.

Authors:  Christina T Kozycki; Noella Umulisa; Stephen Rulisa; Emil I Mwikarago; Jean Pierre Musabyimana; Jean Pierre Habimana; Corine Karema; Donald J Krogstad
Journal:  Malar J       Date:  2017-03-20       Impact factor: 2.979

7.  Performance comparison of CareStart™ HRP2/pLDH combo rapid malaria test with light microscopy in north-western Tigray, Ethiopia: a cross-sectional study.

Authors:  Daniel Getacher Feleke; Shambel Tarko; Haftom Hadush
Journal:  BMC Infect Dis       Date:  2017-06-06       Impact factor: 3.090

8.  A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene deletions in multiple strain infections of Plasmodium falciparum.

Authors:  Tobias Schindler; Anna C Deal; Martina Fink; Etienne Guirou; Kara A Moser; Solomon M Mwakasungula; Michael G Mihayo; Said A Jongo; Prosper P Chaki; Salim Abdulla; Paulo C Manrique Valverde; Katherine Torres; Jose R Bijeri; Joana C Silva; Stephen L Hoffman; Dionicia Gamboa; Marcel Tanner; Claudia Daubenberger
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

Review 9.  Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting.

Authors:  Qin Cheng; Michelle L Gatton; John Barnwell; Peter Chiodini; James McCarthy; David Bell; Jane Cunningham
Journal:  Malar J       Date:  2014-07-22       Impact factor: 2.979

10.  Prevalence of pfhrp2 and/or pfhrp3 Gene Deletion in Plasmodium falciparum Population in Eight Highly Endemic States in India.

Authors:  Praveen Kumar Bharti; Himanshu Singh Chandel; Amreen Ahmad; Sri Krishna; Venkatachalam Udhayakumar; Neeru Singh
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.